FDA
label_change
· 2020-07-28
FDA Approved: FASLODEX — Supplemental Application (AstraZeneca Pharmaceuticals LP)
Summary
FDA approved a supplemental labeling application for FASLODEX (fulvestrant) from AstraZeneca Pharmaceuticals LP. The update relates to labeling for this breast …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for FASLODEX (FULVESTRANT)